SCL Science Inc. (KOSDAQ:246960)

South Korea flag South Korea · Delayed Price · Currency is KRW
2,635.00
-10.00 (-0.38%)
At close: Aug 6, 2025, 3:30 PM KST
-0.38%
Market Cap89.18B
Revenue (ttm)5.87B
Net Income (ttm)-4.73B
Shares Out33.97M
EPS (ttm)-162.49
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume53,881
Average Volume221,637
Open2,665.00
Previous Close2,645.00
Day's Range2,600.00 - 2,665.00
52-Week Range1,882.50 - 5,110.00
Beta0.92
RSI42.57
Earnings DateAug 12, 2025

About SCL Science

SCL Science Inc. produces medical hemostatic agents using biomimetic technology. Its products includes BiMM (Bio-inspired Medical Materials) that reacts immediately with blood; Endoseal which is used for the specialized indication of gastrointestinal bleeding; InnoSeal, a hemostatic agent that is used in various surgical fields such as cardiology, radiology, and neurosurgery; Jelly Seal, a hemostasis and sealing products; STOP, a non-bleeding intravascular injection; Film that prevents leakage at intestinal and vascular anastomosis sites; and I... [Read more]

Industry Orthopedic, Prosthetic, and Surgical Appliances and Supplies
Founded 2010
Employees 62
Stock Exchange KOSDAQ
Ticker Symbol 246960
Full Company Profile

Financial Performance

In 2024, SCL Science's revenue was 4.74 billion, an increase of 258.30% compared to the previous year's 1.32 billion. Losses were -3.73 billion, -25.79% less than in 2023.

Financial Statements

News

There is no news available yet.